-transparent.png){kind=logo}
PRL responsitivity after Vaso-active intestinal Peptide (VIP) infusion was studied during a Dopamine (DA) infusion, in normal women and women with a prolactinoma. VIP alone (6.2 micrograms/min., 12 min.) increases PRL in normal females, but does not remove DA-induced PRL-decrease (1 microgram X kg X X min.-1). It has no effect in women with prolactinoma. In these women, PRL increases when VIP is administered at the 200th minute of DA infusion (1 microgram X kg/min.). A PRL release by VIP in women with a prolactinoma, could imply the restitution of a DA inhibitory control. The same dose of VIP does not modify PRL, when administered during a 4 microgram X kg/min. infusion of DA, in women with a prolactinoma.
D Tater, and
G Charpentier, and
G Besson, and
G Rosselin, and
J P Bercovici
October 1976,
Lancet (London, England),
D Tater, and
G Charpentier, and
G Besson, and
G Rosselin, and
J P Bercovici
May 1983,
Clinical endocrinology,
D Tater, and
G Charpentier, and
G Besson, and
G Rosselin, and
J P Bercovici
March 1985,
European journal of pharmacology,
D Tater, and
G Charpentier, and
G Besson, and
G Rosselin, and
J P Bercovici
January 1978,
Journal of endocrinological investigation,
D Tater, and
G Charpentier, and
G Besson, and
G Rosselin, and
J P Bercovici
February 1985,
Neurosurgery,
D Tater, and
G Charpentier, and
G Besson, and
G Rosselin, and
J P Bercovici
March 1985,
European journal of pharmacology,
D Tater, and
G Charpentier, and
G Besson, and
G Rosselin, and
J P Bercovici
January 1986,
European journal of clinical pharmacology,
D Tater, and
G Charpentier, and
G Besson, and
G Rosselin, and
J P Bercovici
February 1976,
Lancet (London, England),
D Tater, and
G Charpentier, and
G Besson, and
G Rosselin, and
J P Bercovici
July 1974,
The Journal of clinical endocrinology and metabolism,
D Tater, and
G Charpentier, and
G Besson, and
G Rosselin, and
J P Bercovici
January 1992,
Endokrynologia Polska,
